Inhibrx Secures $75M Loan, Details Key Clinical Milestones & BLA Submission for Ozekibart
INBX has more than doubled off its 52-week low of $10.805.
Summary
Inhibrx Biosciences reported Q4 and FY2025 financial results, secured a new $75 million loan, and outlined a robust pipeline of upcoming clinical data readouts and a Biologics License Application submission for ozekibart.
Key Events · Earnings and Guidance · INBX
-
Secured $75 Million Loan
The company entered into an amendment to its Loan and Security Agreement with Oxford Finance, LLC, receiving gross proceeds of $75.0 million on March 18, 2026, significantly enhancing liquidity.
-
BLA Submission for Ozekibart Planned
Inhibrx expects to submit a Biologics License Application (BLA) for ozekibart for unresectable or metastatic conventional chondrosarcoma to the FDA early in the second quarter of 2026.
-
Multiple Clinical Data Readouts Expected
The company plans to announce progression-free survival (PFS) data for ozekibart in colorectal cancer in Q2 2026, and interim objective response rate (ORR) data for INBRX-106 in HNSCC in Q2 2026, with further data later in the year.
-
FY2025 Financial Results Reported
Inhibrx reported a net loss of $140.1 million for the fiscal year 2025, with cash and cash equivalents of $124.2 million as of December 31, 2025, prior to the new loan.
Analysis · INBX · Life Sciences
This filing provides a comprehensive update on Inhibrx's financial position and significant progress across its clinical pipeline. The $75 million loan substantially bolsters the company's cash reserves, extending its operational runway. Critically, the company is on track to submit a Biologics License Application for ozekibart in chondrosarcoma in early Q2 2026, a major step towards potential commercialization. Additionally, multiple data readouts for both ozekibart and INBRX-106 are anticipated throughout 2026, offering several potential catalysts for the stock. While the company reported a net loss for the year, this is typical for a clinical-stage biotech, and the new financing combined with clear pipeline advancement provides a strong positive signal.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.3% of the 1324 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBX was trading at $64.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.5M. The 52-week trading range was $10.81 to $94.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.